3H-spiroperidol binding to lymphocytes has been proposed as
Introduction
In recent years research in the field of psychiatry focused on the evaluation of biological markers. For reasons of clarity it is of bene,~t to distinguish state-dependent (state) from state-independent (trait) markers. A state-independent feature could improve diagnostic validity and identify subgroups. Moreover, it might make it possible to identify individuals at risk. Recently, increased binding of 3H-spiroperidol to peripheral lymphocytes was reported to be a trait marker in schizophrenic patients (Boedy and Ackenheil 1987) .
The pathophysiology of schizophrenia is still not known. To date the dopamine hypothesis of schizophrenia is favored, since antipsychotic drugs are thought to act by blocking D2 dopamine receptors (Seeman et al 1976) . Previous evidence from postmortem studies that showed significantly increased striated D2 doparnine receptors in schizophrenic patients Mita et al 1986) has recently ,been ascribed to neuroleptic treatment prior to death (Kornhuber et al 1989) . In vivo s~xdies using positron emission tomography (PET) have demonstrated elevated D2 dopamine receptors in schizophrenia (Crawley et al 1986; Wong et al 1986) , but these findings could not be replicated in other studies (Farde et al 1~88; Martinot et al 19°0) .
N. Wodarz et al LeFur et al (1980a) initially reported the presence of 3H-spiroperidol binding sites on rat and human peripheral lymphocytes as a model of a peripheral D2 dopamine receptor site. Consequently, in agreement with the dopamine hypothesis, a significant and selective increase in binding capacity (Bm~) for 3H-spiroperidol in lymphocytes of schizophrenic patients was described (LeFur et al 1983; Rotstein et al 1983; Bondy et al 1984; Ha[bach and Henning 1989; Grodzicki et al 1990) . However, selection criteria of patients, methodological details and even Bm~ and Kd values of healthy subjects have differed widely between research groups.
A similar increase of Bm~ was reported in relatives of schizophrenics (Bondy and Ackenheil 1987) and suggests increased 3H-spiroperidol binding as a genetic vulnerability marker for schizophrenia. Interestingly, a decreased binding capacity has been detected in patients with idiopathic Parkinson's disease (LeFur etal 1980b; Czlonkowska et al 1987; Bondy et al 1989) .
In contrast, considerable effert in various laboratories to cGrroborate these results failed (Rloxbam et al !981; F'ieminger et al 1982; Maloteaux et al !982; Shaskan et al 1983; Feenstra et al 1989; Rao et al 1990) . In view of the potential clinical relevance and the variety of pitfalls inherent in binding assays using viable cells., the present study reevaluated some methodological issues, including the mathematical procedures applied to analyze the data.
Methods

Subjects
Venous blood was collected from 12 healthy men [mean age 28.1 __. 13.1 (__.SD) years] between 8:00 and 10:00 AM Subjects with any present illness or under medication, alcohol or nicotine abusers, and persons with a history of stressful life events during the month prior to the investigation were excluded.
To control tbr constancy and reproducibility, binding parameters of lymphocytes from three subjects were measured in blood samples obtained at least on two separate days. The infl:lence of storage on composition of cell suspensions was studied in three subjects where the EDTA-blood samples were kept for I, 2, 3, 5, 8, 10, and 12 hr at room temperature.
Cell Preparation
Peripheral blood mononuclear cells (PBMC) g ere prepared immediately after venipuncture from EDTA-blood by sodium metrizoate-Ficoll density gradient centrifugation, as described elsewhere in detail (Wodarz et al 1991) . Briefly, blood was diluted with Hanks Balanced Salt Solution (HBSS) without Ca 2 + and Mg 2+ 1/1 (v/v) and layered carefully on sodium metrizoate-Ficoli. After centfifugation for 30 min (300 g, 23°C), the lymphocyte,,~ were obtained f~ona the interphase and the granulocytes from the pellet (hemolysis of erythrocytes with 0.8% ammonium chloride). Lymphocytes and granuiocytes were washed three times !n Hanks Balanced Salt Solution without Ca 2+ and Mg 2+ [1/10 (v/v) ; 100 g for 10 rain]. The final cell count was performed with a Coulter Counter (Model $5, Coulter Electronics Ltd, GB). Viability of cells always exceeded 98%, as judged from their ability to exclude trypan blue (Pappenheimer 1917) . Enriched B and T lymphocytes were obtained after culture of unfractionated PBMC for 10 days in culture 1992;31:291-3o3 medium supplemented with 10 Ixg/ml pokeweed mitogen (PWM) or 10 Ixg/ml phytohemagglutinin A (PHA). Routine staining was performed to ensure a constant composition of cell suspensions.
Membrane Preparation
Crude lymphocyte membranes were prepared from one individual by repeated freeze thawing at -80°C. The preparation was hemogenized with a Teflon homogenizer with six up-and-down strokes at 1000 rpm. The homogenate was washed three times in HBSS without Ca 2+ and ~dg 2+ (20.000 g for 15 min) and used immediately afterwards for a saturation experiment. About 13 Ixg per well membrane protein was used. This corresponded to the amount of viable cells in the binding assays. Protein was determined according to Lowry et al (1951) .
Binding Assays
3H-spiroperidol binding assays were performed immediately after cell separation using viable cells (except where otherwise stated). Cells were suspended in HEPES (25 mmol/L) buffered HBSS, pH 7.4, including 1.3 mmol/L Ca 2+ and Mg 2+. To determine binding parameters, cells were incubated with ten different concentrations of 3H-spiroperidol (30 pmol/L to 3 nmol/L) in the presence or absence of I l~mol/L (+)-butaclamol in 96-wen microtiter plates (NUNC, Sweden). Equilibrium was achieved by incubation at 37°C for 60 min in a humidified atmosphere (5% CO2; 95% air). To determine saturability of binding, 3H-spiroperidol concentrations up to 300 nmol/L were used. Free was separated from bound ligand by rapid filtration through polyethyleneimine (PEI; 0.3%; Sigma, St. Louis, USA)-pretreated Whatman GF/C filters (Whatrnan, Maidstone, GB) with a Titertek semiautomatic cell harvester (How Laboratories, Inc., Rockville, MD) followed by an 1 l-see wash with ice-cold HBSS. The radioisotope was measured by a standard liquid scintillation count in a Beckman LS 5000 TD counter at an efficiency of about 54%. All assays were routinely performed in duplicate, except where otherwise stated.
Determination of Unspecific Filter Binding
To determine unspecific binding of 3H-spiroperidol to the widely used Whatman GF/B and Whatman GF/C glass-fiber filters, a binding assay was performed as described above without addition of cells. Different methods were tested to reduce unspecific binding of radioligand to the glass-fiber filters (e.g., extended washing time, pretreatment of filters with different concentrations of the polycationic polyethylenimine).
Displacement of 3H-Sp,~roperidol Binding
Various concentrations of ( + )-and (-)-butaclamol (10-~°-10 -2 mol/L) and GBR 12909 were used to displace 3FI-spiroperidol from its binding site. Culture medium consisted of Rosewell Park Memorial Institute Medium (RPMI) 1640 (Boehringer, Mannheim, Germany) supplemented with 2 mmol/L L-glutamate, 0.1 mg/ml gentamycine, and 10% (v/v) fetal calf serum (all Bioehrom KG, Berlin, Germany). Hanks Balanced Salt Solution was obtained from Bioehrom KG (Berlin, Germany), HEPES from Serva Chemicals (Heidelberg, Germany), and (+)-and (-)-butaclarnol from Research Biochemicals Inc. (Wayland, USA). All dilutions were made with HBSS. Because some subsets of PBMC are known to adhere to glassware, only plastic material was used throughout the experiments.
Data Analysis
The term "displaceable binding" defines the difference between binding in the absence and in the presence of I Ixmol/L ( + )-butaclamol. Kd and Bm~x values were derived from computerized iterative nonlinear regression analysis (Enzfitter, Elsevier Biosoft). The Enzfitter software offers the option of weighing the data statistically and excluding "outliers." The same results could be obtained by excluding samples with a coefficient of variation within a single experiment exceeding 10%.
The following equations were used to apalyze the data and to fit the binding curves: 
To determine whether the increase of goodness of fit for a model with additional parameters was significantly more than could be expected on the basis of chance alone, a reliable F test was applied:
where S~ and SS2 are the residual sums o' , ]uares of the deviations of the points to the fitted curve, and ,:lf~ and dr2 are the assoeiatea degrees of freedom (numbers of data points minus number of parameters) for the original model and the model with additional parameters, respectively (Munson and Rodbard 1980; Bardsley and McGinlay 1987) .
Results
Separation of Free from Bound 3H-Spiroperidol
Using Whatman GF/B filters, 50%-80% of total binding was unspecific binding of radioligand to filter material (Figure 1 to 65%-90% in the presence of ( + )-butaclamol ( Figure 1) . Consequently, the calculated displaceable binding decreased substantially. Figure I demonstrates that extended washing halved unspecific filter binding. Pretreating Whatman GF/C filters (results with other filter material are not shown) with 0.3% polyethyleneimine (PEI) (Bruns et al 1983) reduced unspecific filter binding to 5%-10% of total binding. Moreover, displaceable binding increased to 40%-60% of total binding and the experimental intraassay and interassay scattering decreased. The coefficient of variance without PEI was 0.36; with PEI, it was 0.09.
Displacement of 3H-$piroperidol Biw in8
The enantiomers of butaclamol exhibite¢, r.o stereoselectivity with high (> 2 nmol/L) concentrations of 3H-spiroperidol (Figure 2al . However, by using low (< 1 nmol/L) concentrations of 3H-spiroperidol ( +)-bu~aclamol was about 8 times more potent than (-)-butaclamol ( Figure 2b ). GBR 12909, a selective dopamine uptake inhibitor (Heikkila and Manzino 1984) , was about 100 times more potent than (-)-butaclamol in displacing low concentrations of 3H-spiroperidol, but it was hardly effective with high (> 2 nmol/L) concentrations of radioligand.
3H-Spiroperidol Binding to Subsets of Peripheral Blood Mononuclear Cells and Membrane Preparations
We investigated 3H-spiroperidol binding to unfractionated lymphoc3~tes, to enriched B and T lymphocyte-suspensions, and tO granulocytes. In crude membrane preparations we were unable to detect displaceable binding.
Saturation Experiments
Our experiments in healthy volunteers revealed a biphasic saturation curve with an initial pan at low ligand concentrations (< 1 nmol/L), which might be interpreted as a saturable binding site and a second linear part with higher ligand concentrations (1-300 nmol/L), which is not saturable (Figure 3 ). The mathematical methods described above for the calculation of Bm~ and Kd values were applied to this atypically shaped saturation curve (Table 1 ).
In 10 of 12 individuals tested, it was not possible to obtain Bn~ and Kd values of two saturable binding sites.
Because the goodness of fit will always improve when additional parameters are added to a model, we applied a reliable F test for model discrimination (Munson and Rodbard 1980; Bardsley and McGinlay 1987) . This shows that the model of one specific and one nonspecific binding site significantly improves the goodness of fit, and is preferable to the simpler model of one single site in the ligand concentration range 0.03-3 ntno]/L 3H-spiperone (F = 6.67, dfm -8, df2 ffi 7, p < 0.05). The single-site model, which omits Table 2 and SD in Table 1 ).
Discussion
In line with the dopamine hypothesis, LeFur et al (1980a LeFur et al ( , 1983 reported an increase in 3H-spiroperidol binding sites on peripheral lymphocytes in schizophrenic patients and a decrease of these binding sites in idiopathic Parkinson's disease. Subsequently, these exciting results were questioned, because even the methodology applied could not be constantly reproduced in other laboratories. The potential clinical importance of 3H-3H-Spiroperidol Binding to PBMC in Man spiroperidol binding to lymphocytes as a "vulnerability marker of schizophrenia" (Bondy and Ackenheil 1987) led us to reinvestigate the most striking pitfalls in binding assays using viable cells.
Separating free from bound ligand is a critical point in dete__rmination of the chAracteristic binding parameters 8m~ and Kd. Due to a steady-state dissociation constant in the nanomolar range, time for the separation procedure should not exceed 30--60 sec. Most investigators used a filtration assay, because of its unsurpassed speed, efficiency, and easy handling (Fleminger et al 1982; Maloteaux et al 1982; Bidart et al 1983; LeFur et al 1983; Shasken et al 1983; Itzchaky et al 1989) . A pertinent example of the most dangerous pitfall of this technique is the stereospecific binding of mdiolabeled opiates to glass-fiber filters reported by Pastemak and Snyder (1975) . With mdiolabeled spiroperidol only Fleminger et al (1982) mentioned a filter binding of 50% when using the most commonly employed Whatman GF/B filters. Other investigators seem not to have controlled for this phenomenon (Maloteaux et al 1982; Bidart et al 1983; LeFur et al 1983; Shaskan et al 1983; Itzeh',&y et al 1989) . As demons~lted for various other receptor assays (Maayani and Weinstein 1980; Ito et al 1986) the apparent Kd and Bm~ values
were not meaningful wii~hc,Jt coping with this phenomenon. In our experiments pretreatment of Whatman GF/C fii~ers with 0.3% polyethyleneimine (Brans et al 1983; Gundlach et al 1984) finally reduc~:d ,mspecific filter binding to 5%-10% of total binding. Moreover, displaceable binding in~,:.'r~.ased to 40%--60% of total binding and the experimental intraassay and interassay ~cattering decreased. Conflicting results h~w~ been reported for the distribution of 3H-spiroperidol binding sites on different subtypes of human peripheral blood mononuclear cells. Bidart et al (1983) reported that B lymphocytes had about double the capacity of T lymphocytes to bind this ligand, whereas Uzan et al (1981) found displaceable binding only on B cells. In agreement with Uzan et al (1981) we found displaceable binding only with unfractionated lymphocytes and in enriched B cell fractions. Because the amount of contaminating granulocytes contributes ".~ a decrease in percentage of displaceable binding, especially in the low concentrati~on range of radiolabeled spiroperidol, it is of critical importance to control for a constraint composition of investigated cell suspensions. One possibility would be to investigatle pure B cell suspensions, but this needs considerable additional methodological effort. If unfractionated cell suspensions are examined, it is essential to proceed immediately after blood drawing. Some groups did not refer to that (Bloxham et al 1981; Fleminger et al 1982; Bidart et al 1983; Rotstein et al 1983; Bondy and Ackenheil 1987; Feenstra et al 1989; Itzchaky et al 1989) . For example, this might be one explanation for the failure of Feenstra et al (1989) to detect any displaceable binding in human lymphocytes, since this group proceeded 18 hr after venipuncture and .did not control for granulocyte contamination.
The weak or missing stereoselecfivity of (+)-and (-)-butaclamol in displacing 3H-spiroperidol from its lymphocytic binding sites is a further topic of controversy. Bloxham et al (1981) , Maloteaux et al (1982) , Fleminger et al (1982) , and Rotstein et al (1983) used ligand concentrations of 4 or 5 nmol/L in displacement experiments. Indeed, at these relatively high (>2 nmol/L) ligand concentrations, the stereoisomers of butaclamol exhibiteet no stereoselectivity. However, when low (< 1 nmol/L) concentrations of 3H-spiroperidol were used in our experiments, ( + )-butaclamol was about 8 times more potent than (-)~butaclamol (Figure 2b ). This might be indicative Of a specifi~ binding site in the low concentration range of radiolabeled spiroperidol. But it is very unlikely that it resembles the central D2 dopamine receptor', since (+)-butaclamol is about 1000 times more potent than (-)-butaclaniol in displacing 3H-spiroperidol from striatal D2 dopamine receptors. Moreover, dopamine uptake inhibitors arc ineffective at tile neuronal D2 receptor (Seeman 1981; Hitri et al 1991;  our own data not shown).
Provided that these technical problems are considered, a final crucial step is the mode of data analysis. Rotstein et al (19~3) and Itzchaky et al (1989) were not able to calculate any binding parameters and therefore used counts per minute (cpm) of displaeeable binding for comparing schizophrenic with healthy subjects. Due to the atypically shaped saturation curve, various ways of calculation of Bm~ and Kd values have been used in the literature.
It must be noted that none of the authors has statistically analyzed the model used. Oar validation of these models by a reliable F test demonstrates that both the single-site model, which omits the nonsaturable part (ligand concentration range 0.05-3 nmol/L; Halbach and Henning 1989) , and the complex model of one saturable and one nonsaturable site By using the model of two different binding sites, we were unable to achieve two Kd and 8m~ values in 10 of 12 individuals tested. Moreover, with concentrations of radioligand above 1 nmol/L only a linear nonsaturable increase in binding could be observed, in accordance with Feenstra et ai (1989) . As long as the molecular nature of the "spiroperidoi binding site" is unknown, the complex model of one saturable and one nonsaturable site (iigand concentration range 0.03-3 nmol/L; Bondy and Ackenheil 1987) is the most adequate.
Ba~ed on these different calculation strategies, our Bm~ and Kd values in healthy subjects corresponded quite well to those of other research groups (Table l) . The remaining discrepancies might be explained by such pitfalls as variable composition of investigated cell suspensions (Bidart et al 1983; Benday and Ackenheil 1987) and uncon~trolled unspecific filter binding (LeFur et al 1983~. Grodzicki et al (1990 analyzt,d the ligand concentration range 0.07-1.2 nmol/L only'. This confirms the need to define exactly the details of experimental ~ad mathematical procedures before comparing the results reported by different groups. 111e molecular naturt: of the "3H-spiroperidol binding site" is still unknown. Pharmacological characteristic~ are quite differ~:nt from the central D2 dopamine receptor with high (Bloxham et al 1981; Fleminger et al 1982; Maloteaux et al 1982) as well as low concentrations of aH-spil~rone (see stereoselectivity of butacl~vl-enantiomers). Moreover, ¢e~,ls have to be viable to demonstrate binding at all (Shaskan et al 1983; Feenstra et al 1989; Roe et al 199C~;  our own results), whereas neuronal D2 sites can be detected in membrane preparations. Taken together with preliminary new results in our ( Figure  2b ) and other laboratories (Bondy et al 1990) with the specific dopamine uptake inhibitor GBR 12909, the "high-affinity site" resembles an active, energy-dependent transport site and not a true receptor. On the other hand, the possibilky that this "binding site" might resemble one of the novel clopamine receptors (D3,4,5; Sokoloff et al 1990; Van Tel et al 1991; Sunahara et al 1991) could not be definitely excluded. The "nonGpeeific, nonsaturable" part might represent an unspecific uptake into the cells (Fleminger et al 1982; Maloteaux et al 1983) .
Ap~rt from not ~xactly knowing the pharmacological and molecular nature of the "3H-spiroperidol binding site" in peripheral lymphocytes, the findings m schizophrenia of
